Postneoadjuvant Trastuzumab Deruxtecan Results in Higher Likelihood of iDFS Among Patients with HER2-positive EBC with Residual Invasive Disease After Neoadjuvant Treatment By Ogkologos - December 12, 2025 511 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the interim analysis of the DESTINY-Breast05 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR FDA Grants Accelerated Approval to Pembrolizumab for Locally Recurrent Unresectable or... November 16, 2020 Regular Exercise May Help Guard Breast Cancer Patients From Chemo Brain August 20, 2021 EMA Recommends Extension of Indications for Serplulimab April 22, 2026 Working to Raise Prostate Cancer Awareness: A Patient Advocate’s Story January 25, 2022 Load more HOT NEWS This Saturday: National Prescription Drug Take-Back Day Moving target – retrotransposable elements and cancer Can a Biopsy Make My Cancer Spread? Five Questions with…Jennifer.
